Atrial fibrillation is responsible for more disability than any other cardiac arrhythmia because
of its high incidence and the considerable potential for adverse outcomes. There is …

Background: Randomized trials have shown a beneficial effect of anticoagulation with
warfarin to prevent stroke in atrial fibrillation. It is not known whether the same effect will be …

ContextWarfarin has been shown to be highly efficacious for preventing thromboembolism in
atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is …

Purpose: To characterize the efficacy and safety of anticoagulants and antiplatelet agents for
prevention of stroke in patients with atrial fibrillation. Data Sources: Randomized trials …

Atrial fibrillation (AF) is an important risk factor for stroke. According to a pooled analysis of
controlled clinical trials with warfarin, anticoagulation therapy reduces stroke risk by 62 …

New anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer
a number of advantages over warfarin, for both the clinician and patient, including a …

Clinical trials during the past 20 years have revolutionized the antithrombotic management
of atrial fibrillation. Based on consideration of 30 randomized trials involving 29,017 …

Atrial fibrillation confers a 5-fold increase in risk of stroke. A number of drugs aimed at
reducing this risk have been tested in randomized controlled trials. These include …

ContextAtrial fibrillation, a common disorder that affects nearly one sixth of the population
aged 75 years and older, is a major risk factor for stroke. ObjectivesTo review and evaluate …

OBJECTIVE To evaluate appropriateness of antithrombotic use to prevent stroke in atrial
fibrillation. DESIGN, PATIENTS 344 patients with atrial fibrillation, stratified by age, were …